Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial.

Mulligan MJ, Stapleton JT, Keitel WA, Frey SE, Chen WH, Rouphael N, Edupuganti S, Beck A, Winokur PL, El Sahly HM, Patel SM, Atmar RL, Graham I, Anderson E, El-Kamary SS, Pasetti MF, Sztein MB, Hill H, Goll JB; DMID 08-0006 Tularemia Vaccine Study Group.

Vaccine. 2017 Aug 24;35(36):4730-4737. doi: 10.1016/j.vaccine.2017.07.024. Epub 2017 Jul 24.

2.

CD11a and CD49d enhance the detection of antigen-specific T cells following human vaccination.

Christiaansen AF, Dixit UG, Coler RN, Marie Beckmann A, Reed SG, Winokur PL, Zimmerman MB, Varga SM, Wilson ME.

Vaccine. 2017 Jul 24;35(33):4255-4261. doi: 10.1016/j.vaccine.2017.06.013. Epub 2017 Jun 27.

3.

Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial.

Jackson LA, Frey SE, El Sahly HM, Mulligan MJ, Winokur PL, Kotloff KL, Campbell JD, Atmar RL, Graham I, Anderson EJ, Anderson EL, Patel SM, Fields C, Keitel W, Rouphael N, Hill H, Goll JB.

Vaccine. 2017 Mar 23;35(13):1675-1682. doi: 10.1016/j.vaccine.2017.02.032. Epub 2017 Feb 27.

PMID:
28256358
4.

Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination.

Hoft DF, Lottenbach K, Goll JB, Hill H, Winokur PL, Patel SM, Brady RC, Chen WH, Edwards K, Creech CB, Frey SE, Blevins TP, Salomon R, Belshe RB.

J Infect Dis. 2016 Oct 1;214(7):1020-9. doi: 10.1093/infdis/jiw310. Epub 2016 Jul 20.

5.

Increased Mortality Rates Associated with Staphylococcus aureus and Influenza Co-infection, Maryland and Iowa, USA(1).

McDanel JS, Perencevich EN, Storm J, Diekema DJ, Herwaldt L, Johnson JK, Winokur PL, Schweizer ML.

Emerg Infect Dis. 2016 Jul;22(7):1253-6. doi: 10.3201/eid2207.151319.

6.

Association between microbial characteristics and poor outcomes among patients with methicillin-resistant Staphylococcus aureus pneumonia: a retrospective cohort study.

McDanel JS, Perencevich EN, Diekema DJ, Winokur PL, Johnson JK, Herwaldt LA, Smith TC, Chrischilles EA, Dawson JD, Schweizer ML.

Antimicrob Resist Infect Control. 2015 Dec 14;4:51. doi: 10.1186/s13756-015-0092-1. eCollection 2015.

7.

Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine.

Mbawuike IN, Atmar RL, Patel SM, Corry DB, Winokur PL, Brady RC, Chen WH, Edwards KM, Creech CB, Walter EB Jr, Frey SE, Belshe RB, Goll JB, Hill H, Keitel WA.

Vaccine. 2016 Jan 20;34(4):547-554. doi: 10.1016/j.vaccine.2015.11.055. Epub 2015 Dec 4.

8.

Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine.

Winokur PL, Patel SM, Brady R, Chen WH, El-Kamary SS, Edwards K, Creech CB, Frey S, Keitel WA, Belshe R, Walter E, Bellamy A, Hill H.

J Infect Dis. 2015 Aug 15;212(4):525-30. doi: 10.1093/infdis/jiv087. Epub 2015 Feb 23.

9.

Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons ≥18 Years Old.

Keitel WA, Jackson LA, Edupuganti S, Winokur PL, Mulligan MJ, Thornburg NJ, Patel SM, Rouphael NG, Lai L, Bangaru S, McNeal MM, Bellamy AR, Hill HR; VTEU H3N2v Vaccine Study Work Group.

J Infect Dis. 2015 Aug 15;212(4):552-61. doi: 10.1093/infdis/jiv056. Epub 2015 Feb 3.

10.

Phase II randomized, double-blinded comparison of a single high dose (5×10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1×10(8) TCID50) in healthy vaccinia-naïve individuals.

Frey SE, Winokur PL, Hill H, Goll JB, Chaplin P, Belshe RB.

Vaccine. 2014 May 13;32(23):2732-9. doi: 10.1016/j.vaccine.2014.02.043. Epub 2014 Mar 6.

11.

Safety and immunological outcomes following human inoculation with nontypeable Haemophilus influenzae.

Winokur PL, Chaloner K, Doern GV, Ferreira J, Apicella MA.

J Infect Dis. 2013 Sep 1;208(5):728-38. doi: 10.1093/infdis/jit238. Epub 2013 May 28.

12.

Analysis of nontypeable haemophilus influenzae phase-variable genes during experimental human nasopharyngeal colonization.

Poole J, Foster E, Chaloner K, Hunt J, Jennings MP, Bair T, Knudtson K, Christensen E, Munson RS Jr, Winokur PL, Apicella MA.

J Infect Dis. 2013 Sep 1;208(5):720-7. doi: 10.1093/infdis/jit240. Epub 2013 May 28.

13.

Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario.

Frey SE, Winokur PL, Salata RA, El-Kamary SS, Turley CB, Walter EB Jr, Hay CM, Newman FK, Hill HR, Zhang Y, Chaplin P, Tary-Lehmann M, Belshe RB.

Vaccine. 2013 Jun 24;31(29):3025-33. doi: 10.1016/j.vaccine.2013.04.050. Epub 2013 May 9.

14.

Long-term risk for readmission, methicillin-resistant Staphylococcus aureus (MRSA) infection, and death among MRSA-colonized veterans.

Quezada Joaquin NM, Diekema DJ, Perencevich EN, Bailey G, Winokur PL, Schweizer ML.

Antimicrob Agents Chemother. 2013 Mar;57(3):1169-72. doi: 10.1128/AAC.01968-12. Epub 2012 Dec 17.

15.

Safety and immune responses in children after concurrent or sequential 2009 H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.

Frey SE, Bernstein DI, Gerber MA, Keyserling HL, Munoz FM, Winokur PL, Turley CB, Rupp RE, Hill H, Wolff M, Noah DL, Ross AC, Cress G, Belshe RB.

J Infect Dis. 2012 Sep 15;206(6):828-37. doi: 10.1093/infdis/jis445. Epub 2012 Jul 16.

16.

Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009.

Chen WH, Winokur PL, Edwards KM, Jackson LA, Wald A, Walter EB, Noah DL, Wolff M, Kotloff KL; Pandemic H1N1 Vaccine Adult Study Group.

Vaccine. 2012 Jun 13;30(28):4240-8. doi: 10.1016/j.vaccine.2012.04.044. Epub 2012 Apr 23.

17.

Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIV-infected adults: a randomized clinical trial.

El Sahly HM, Davis C, Kotloff K, Meier J, Winokur PL, Wald A, Johnston C, George SL, Brady RC, Lehmann C, Stokes-Riner A, Keitel WA.

J Infect Dis. 2012 Mar 1;205(5):703-12. doi: 10.1093/infdis/jir837. Epub 2012 Jan 24.

18.

Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults.

Frenck RW Jr, Belshe R, Brady RC, Winokur PL, Campbell JD, Treanor J, Hay CM, Dekker CL, Walter EB Jr, Cate TR, Edwards KM, Hill H, Wolff M, Leduc T, Tornieporth N.

Vaccine. 2011 Aug 5;29(34):5666-74. doi: 10.1016/j.vaccine.2011.06.010. Epub 2011 Jun 23.

19.

BD Phoenix and Vitek 2 detection of mecA-mediated resistance in Staphylococcus aureus with cefoxitin.

Junkins AD, Lockhart SR, Heilmann KP, Dohrn CL, Von Stein DL, Winokur PL, Doern GV, Richter SS.

J Clin Microbiol. 2009 Sep;47(9):2879-82. doi: 10.1128/JCM.01109-09. Epub 2009 Jul 22.

20.

Emergence of the USA300 strain of methicillin-resistant Staphylococcus aureus in a burn-trauma unit.

Wibbenmeyer LA, Kealey GP, Latenser BA, Diekema DJ, Williams IM, Coffman SL, Winokur PL, Kroeger JS, Lewis RW 2nd, Herwaldt LA.

J Burn Care Res. 2008 Sep-Oct;29(5):790-7. doi: 10.1097/BCR.0b013e3181848b8f.

PMID:
18695604
21.

Strain-relatedness of methicillin-resistant Staphylococcus aureus isolates recovered from patients with repeated infection.

Huang SS, Diekema DJ, Warren DK, Zuccotti G, Winokur PL, Tendolkar S, Boyken L, Datta R, Jones RM, Ward MA, Aubrey T, Onderdonk AB, Garcia C, Platt R.

Clin Infect Dis. 2008 Apr 15;46(8):1241-7. doi: 10.1086/529381.

22.

Distinct gene expression profiles in peripheral blood mononuclear cells from patients infected with vaccinia virus, yellow fever 17D virus, or upper respiratory infections.

Scherer CA, Magness CL, Steiger KV, Poitinger ND, Caputo CM, Miner DG, Winokur PL, Klinzman D, McKee J, Pilar C, Ward PA, Gillham MH, Haulman NJ, Stapleton JT, Iadonato SP.

Vaccine. 2007 Aug 29;25(35):6458-73. Epub 2007 Jul 6.

23.

Antimicrobial drug-resistant Escherichia coli from humans and poultry products, Minnesota and Wisconsin, 2002-2004.

Johnson JR, Sannes MR, Croy C, Johnston B, Clabots C, Kuskowski MA, Bender J, Smith KE, Winokur PL, Belongia EA.

Emerg Infect Dis. 2007 Jun;13(6):838-46.

24.

Association between ceftiofur use and isolation of Escherichia coli with reduced susceptibility to ceftriaxone from fecal samples of dairy cows.

Tragesser LA, Wittum TE, Funk JA, Winokur PL, Rajala-Schultz PJ.

Am J Vet Res. 2006 Oct;67(10):1696-700.

PMID:
17014318
25.

Surveillance in Taiwan using molecular epidemiology for extended-spectrum beta-lactamase-producing Klebsiella pneumoniae.

Yu WL, Winokur PL, Jones RN, Sader HS.

Infect Control Hosp Epidemiol. 2004 Oct;25(10):812-8.

PMID:
15518021
26.

Vaccination success rate and reaction profile with diluted and undiluted smallpox vaccine: a randomized controlled trial.

Talbot TR, Stapleton JT, Brady RC, Winokur PL, Bernstein DI, Germanson T, Yoder SM, Rock MT, Crowe JE Jr, Edwards KM.

JAMA. 2004 Sep 8;292(10):1205-12. Erratum in: JAMA. 2004 Nov 24;292(20):2470.

PMID:
15353533
27.

DNA sequence analysis of regions surrounding blaCMY-2 from multiple Salmonella plasmid backbones.

Giles WP, Benson AK, Olson ME, Hutkins RW, Whichard JM, Winokur PL, Fey PD.

Antimicrob Agents Chemother. 2004 Aug;48(8):2845-52.

28.

Emergence of two Klebsiella pneumoniae isolates harboring plasmid-mediated CTX-M-15 beta-lactamase in Taiwan.

Yu WL, Cheng KC, Wu LT, Pfaller MA, Winokur PL, Jones RN.

Antimicrob Agents Chemother. 2004 Jan;48(1):362-3. No abstract available.

29.
30.

Confirmation of extended-spectrum beta-lactamase-producing Serratia marcescens: preliminary report from Taiwan.

Yu WL, Wu LT, Pfaller MA, Winokur PL, Jones RN.

Diagn Microbiol Infect Dis. 2003 Apr;45(4):221-4.

PMID:
12729989
31.

Molecular epidemiological techniques for Salmonella strain discrimination.

Winokur PL.

Front Biosci. 2003 Jan 1;8:c14-24. Review.

PMID:
12456335
32.

Cefepime MIC as a predictor of the extended-spectrum beta-lactamase type in Klebsiella pneumoniae, Taiwan.

Yu WL, Pfaller MA, Winokur PL, Jones RN.

Emerg Infect Dis. 2002 May;8(5):522-4.

33.

First description of Klebsiella pneumoniae harboring CTX-M beta-lactamases (CTX-M-14 and CTX-M-3) in Taiwan.

Yu WL, Winokur PL, Von Stein DL, Pfaller MA, Wang JH, Jones RN.

Antimicrob Agents Chemother. 2002 Apr;46(4):1098-100.

34.

Antimicrobial susceptibility of bacteria causing urinary tract infections in Latin American hospitals: results from the SENTRY Antimicrobial Surveillance Program (1997).

Sader HS, Jones RN, Winokur PL, Pfaller MA, Doern GV, Barrett T; The SENTRY Study Group, Latin America .

Clin Microbiol Infect. 1999 Aug;5(8):478-487.

35.

Cathelicidin peptides inhibit multiply antibiotic-resistant pathogens from patients with cystic fibrosis.

Saiman L, Tabibi S, Starner TD, San Gabriel P, Winokur PL, Jia HP, McCray PB Jr, Tack BF.

Antimicrob Agents Chemother. 2001 Oct;45(10):2838-44.

36.

Evidence for transfer of CMY-2 AmpC beta-lactamase plasmids between Escherichia coli and Salmonella isolates from food animals and humans.

Winokur PL, Vonstein DL, Hoffman LJ, Uhlenhopp EK, Doern GV.

Antimicrob Agents Chemother. 2001 Oct;45(10):2716-22.

38.

Russian Klebsiella pneumoniae isolates that express extended-spectrum beta-lactamases.

Winokur PL, Eidelstain MV, Stetsiouk O, Stratchounski L, Blahova J, Reshedko GK, Croco MA, Hollis RJ, Pfaller MA, Jones RN.

Clin Microbiol Infect. 2000 Feb;6(2):103-8. No abstract available.

39.
40.

Animal and human multidrug-resistant, cephalosporin-resistant salmonella isolates expressing a plasmid-mediated CMY-2 AmpC beta-lactamase.

Winokur PL, Brueggemann A, DeSalvo DL, Hoffmann L, Apley MD, Uhlenhopp EK, Pfaller MA, Doern GV.

Antimicrob Agents Chemother. 2000 Oct;44(10):2777-83.

41.

Molecular characterization of the beta-lactamases from clinical isolates of Moraxella (Branhamella) catarrhalis obtained from 24 U.S. medical centers during 1994-1995 and 1997-1998.

Richter SS, Winokur PL, Brueggemann AB, Huynh HK, Rhomberg PR, Wingert EM, Doern GV.

Antimicrob Agents Chemother. 2000 Feb;44(2):444-6.

43.
44.

Phenotypic and genotypic characterizations of Chinese strains of Escherichia coli producing extended-spectrum beta-lactamases.

Shen D, Biedenbach DJ, Winokur PL, Pfaller MA, Jones RN.

Diagn Microbiol Infect Dis. 1999 Jul;34(3):159-64.

PMID:
10403094
45.
46.

Recombinant hepatitis A virus antigen: improved production and utility in diagnostic immunoassays.

LaBrecque FD, LaBrecque DR, Klinzman D, Perlman S, Cederna JB, Winokur PL, Han JQ, Stapleton JT.

J Clin Microbiol. 1998 Jul;36(7):2014-8.

49.

Antigenic and immunogenic properties of recombinant hepatitis A virus 14S and 70S subviral particles.

Stapleton JT, Raina V, Winokur PL, Walters K, Klinzman D, Rosen E, McLinden JH.

J Virol. 1993 Feb;67(2):1080-5.

Supplemental Content

Loading ...
Support Center